WILMINGTON, Del. – Saying directors of NovaBay Pharmaceuticals lied to dilute holdings of common stock, shareholders brought a federal class action to rescind the wrongfully granted equity awards.
Follow @bleonardcns
Categories / Securities
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Contempt for Musk clouds jury selection in Twitter takeover trial February 19, 2026
-
Ups and downs for Boeing investors February 18, 2026 -
